Search results
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 3 days agoSales also tumbled 20% to $14.88 billion, but topped forecasts for $13.87 billion. As expected,...
Pfizer lifts profit view on cost cuts, smaller drop in Paxlovid By Reuters
Investing.com· 4 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer (NYSE:PFE) gained through its $43...
CDC Found Evidence COVID-19 Vaccines Caused Deaths
WSAU Wausau· 3 days agoIn an exclusive report by the Epoch Times, U.S. Centers for Disease Control and Prevention (CDC) officials fou...
The CDC Took Out 148 Pages of Essential Information
Mercola· 2 days agoPeople who receive a COVID-19 shot are at increased risk of myocarditis, or inflammation of the heart muscle,1 and pericarditis, which is inflammation of the outer lining of the heart. The public ...
DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative
FOX 59 Indianapolis· 6 days agoIn recent years, the rapid development of artificial intelligence has introduced new possibilities...
TIME100 Health: Katalin Kariko and Drew Weissman
Time Magazine· 3 days agoDr. Drew Weissman was working on developing an HIV vaccine, and Katalin Kariko was struggling to keep her lab open and convince her superiors that her...
Study identifies immunity threshold for protection against COVID-19 in children
Medical Xpress· 5 days agoAll participants received two doses of 10mcg Pfizer/BioNTech mRNA COVID-19 vaccination, 21 days apart. The team followed up with the participants for one year, during which ...
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook - GSK (NYSE:GSK)
Benzinga· 4 days agoVaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand...
Why are nearly half of all recent biotech RNA alliances in Asia-Pacific betting big on...
BioPharma-Reporter· 5 days agoAlmost half of all strategic alliances focused on RNA therapies over the last five years in the...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 2 days agoThursday, Moderna Inc MRNA reported a first-quarter EPS loss of $(3.07), down from an income of...